CompletedNCT00597896
Pramipexole for cognitive difficulties in bipolarity
About this title
Read the official source — NCT00597896Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Glen OaksSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 50
- Sponsor
- Northwell Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00597896
- Official title
Show the full official title
Cognitive Enhancement in Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Glen Oaks
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Northwell Health.
Did this study involve medication?
Yes. The study involved medication, including pramipexole.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
